General MedicationsSUBCUTANEOUSGeneric
OTREXUP PFS
METHOTREXATE
Standard Dose
25MG/ML (25MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview OTREXUP PFS is listed in Drugs@FDA under application 204824 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient METHOTREXATE Form and strength SOLUTION;SUBCUTANEOUS - 25MG/ML (25MG/ML) Sponsor ASSERTIO SPECLTY Submission history Latest submission status date: 2019-12-26 00:00:00.
Structured Monograph
Clinical summary
Approval overview OTREXUP PFS is listed in Drugs@FDA under application 204824 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient METHOTREXATE Form and strength SOLUTION;SUBCUTANEOUS - 25MG/ML (25MG/ML) Sponsor ASSERTIO SPECLTY Submission history Latest submission status date: 2019-12-26 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.